Elan and Wyeth report encouraging results from Phase II Alzheimer’s trial
In the 18-month trial, bapineuzumab appeared to have clinical activity in treating Alzheimer’s disease. The study did not attain statistical significance on the primary efficacy endpoints in the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.